Fundraising Fox
🦊/Companies
Sign in

Verax Biomedical

Marlborough, US · 1 known investors

Find your way into Verax Biomedical

108 people in our graph share verified history with the Verax Biomedical team — schools, employers, funds. One of them is your warm intro.

Jack Thomas Tomarchiounlockedknows YLI REMO VALLEJO · together at Penn State University (overlapped)
×11knows the team · via Ateneo de Manila University

Verax Biomedical develops rapid bacterial contamination detection tests for blood products and tissues intended for transfusion and transplantation. The company serves blood banks, hospitals, and transfusion centers seeking to prevent infectious complications from bacterial growth in stored cellular materials.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

JR
JOE R. SANDERSinChief Marketing & Business Development Officer
YRYLI REMO VALLEJO
YLI REMO VALLEJOinSenior Vice President, Research & DevelopmentYlli Remo Vallejo is an Executive Officer at Verax Biomedical who previously led research and product development teams in medical diagnostics, drugs of abuse testing, and biothreat detection, with expertise in regulatory compliance and multiple FDA product clearances. He holds seven awarded patents and has published work in pesticide immunodetection and immunogenicity testing.
RS
R. SCOTT MCKENZIE, SR.inSr. VP Operations
NA
NANCY A. HORNBAKERinVice President Regulatory Affairs
PR
PAUL RAGUSAinVice President

Board

MGMARC GOLDBERG
MARC GOLDBERGinBoard directorCo-Founder and Managing Partner at Bioventures Investors
JL
JAMES LOUSARARIANBoard director
JD
JOE DEL GUERCIOBoard director
JK
JAMES KOZIARZBoard director
RZ
ROBERT ZIESERLBoard director
BB
BUZZ BENSONBoard director

Investors · 1

Bioventures InvestorsWestborough · $15M – $100M

Reported raises · per SEC filings

Form D private placements

$30.6M disclosed across 4 rounds · 2015–2019

▶$2.5MraisedSep 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James LousararianExecutive Officer, Director
  • Paul RagusaExecutive Officer
  • Joe SandersDirector
  • Robert FlanaganDirector
  • Marc GoldbergDirector
Offering amount
$10.5M
Amount sold
$2.5M
Sales commissions
$425K
Placement agents
Thomas Frederick Zipser
First sale
Sep 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.4MraisedNov 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAMES LOUSARARIANExecutive Officer, Director
  • JOE SANDERSExecutive Officer, Director
  • MARC E. GOLDBERGDirector
  • JOE DEL GUERCIODirector
Offering amount
$24.1M
Amount sold
$11.4M
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.6MraisedJun 2016 · 64 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • PAUL RAGUSAExecutive Officer
  • MARC E. GOLDBERGDirector
  • JAMES KOZIARZDirector
  • JAMES LOUSARARIANExecutive Officer, Director
  • YLI REMO VALLEJOExecutive Officer
  • JOE DEL GUERCIODirector
  • NANCY A. HORNBAKERExecutive Officer
  • JOE R. SANDERSExecutive Officer, Director
  • R. SCOTT MCKENZIEExecutive Officer
Offering amount
$24.5M
Amount sold
$12.6M
First sale
Feb 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedJan 2015 · 61 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAMES KOZIARZDirector
  • JOE R. SANDERSExecutive Officer, Director
  • ROBERT ZIESERLDirector
  • BUZZ BENSONDirector
  • YLI REMO VALLEJOExecutive Officer
  • R. SCOTT MCKENZIE, SR.Executive Officer
  • NANCY A. HORNBAKERExecutive Officer
  • PAUL RAGUSAExecutive Officer
  • MARC GOLDBERGDirector
  • JAMES LOUSARARIANExecutive Officer, Director
  • JOE DEL GUERCIODirector
Offering amount
$4M
Amount sold
$4M
First sale
Jan 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Medscape7 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Verax Biomedical for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Verax raises $12m for platelet test - The Boston Globebostonglobe.com · Oct 2013Verax Biomedical Closes $12MM Funding Round - Verax Biomedicalveraxbiomedical.com · Oct 2013Verax Biomedical, Incorporated Closes $12 Million Funding Round - BioSpacebiospace.com · Oct 2013Verax Biomedical Completes $12m Financing - FinSMEsfinsmes.com · Oct 2013AssureRx drums up $11 million | Funding roundup - MassDevicemassdevice.com · Mar 2011Verax raises $15M to fund platelet testtelegram.com · Oct 2005

Frequently asked questions

What does Verax Biomedical do?
Verax Biomedical develops rapid bacterial contamination detection tests for blood products and tissues intended for transfusion and transplantation. The company serves blood banks, hospitals, and transfusion centers seeking to prevent infectious complications from bacterial growth in stored cellular materials.
Who are Verax Biomedical's investors?
Verax Biomedical's investors include Bioventures Investors.
How much funding has Verax Biomedical raised?
Verax Biomedical has disclosed $30.6M raised across 4 rounds.
Where is Verax Biomedical headquartered?
Verax Biomedical is headquartered in Marlborough, US.